Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistBased on limited metadata, Alternavita received an FDA Warning Letter on May 26, 2020, regarding drug products. Without access to the full letter text or specific subject line, the exact nature of the violations cannot be determined from the available information. The warning was issued under FDA's drug regulatory authority, though the specific issuing office is not identified in the metadata provided. To understand the precise compliance issues cited, the complete Warning Letter would need to be reviewed.